A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis

Trial Profile

A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 28 Jan 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 28 Jan 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top